Aytu BioPharma AYTU Stock
Aytu BioPharma Price Chart
Aytu BioPharma AYTU Financial and Trading Overview
| Aytu BioPharma stock price | 2.25 USD |
| Previous Close | 2.31 USD |
| Open | 2.25 USD |
| Bid | 1.64 USD x 200 |
| Ask | 2.9 USD x 200 |
| Day's Range | 2.17 - 2.32 USD |
| 52 Week Range | 1.65 - 3.07 USD |
| Volume | 25.93K USD |
| Avg. Volume | 41.59K USD |
| Market Cap | 24.15M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.61 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.5 USD |
AYTU Valuation Measures
| Enterprise Value | 19.25M USD |
| Trailing P/E | N/A |
| Forward P/E | -29.999998 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.426681 |
| Price/Book (mrq) | 0.68723273 |
| Enterprise Value/Revenue | 0.34 |
| Enterprise Value/EBITDA | -7.334 |
Trading Information
Aytu BioPharma Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 10.29% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 3.07 USD |
| 52 Week Low | 1.65 USD |
| 50-Day Moving Average | 2.35 USD |
| 200-Day Moving Average | 2.37 USD |
AYTU Share Statistics
| Avg. Volume (3 month) | 41.59K USD |
| Avg. Daily Volume (10-Days) | 27.75K USD |
| Shares Outstanding | 10.73M |
| Float | 7.61M |
| Short Ratio | 7.58 |
| % Held by Insiders | 8.98% |
| % Held by Institutions | 36.58% |
| Shares Short | 407.98K |
| Short % of Float | 4.42% |
| Short % of Shares Outstanding | 3.79% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | June 30, 2026 |
Profitability
| Profit Margin | -60.16% |
| Operating Margin (ttm) | -32.74% |
| Gross Margin | 64.77% |
| EBITDA Margin | -4.63% |
Management Effectiveness
| Return on Assets (ttm) | -3.65% |
| Return on Equity (ttm) | -97.42% |
Income Statement
| Revenue (ttm) | 56.6M USD |
| Revenue Per Share (ttm) | 6.16 USD |
| Quarterly Revenue Growth (yoy) | -32.70% |
| Gross Profit (ttm) | 36.66M USD |
| EBITDA | -2625000 USD |
| Net Income Avi to Common (ttm) | -34117000 USD |
| Diluted EPS (ttm) | -4.61 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 26.72M USD |
| Total Cash Per Share (mrq) | 2.49 USD |
| Total Debt (mrq) | 21.82M USD |
| Total Debt/Equity (mrq) | 62.08 USD |
| Current Ratio (mrq) | 1.123 |
| Book Value Per Share (mrq) | 3.274 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 1.68M USD |
| Levered Free Cash Flow (ttm) | -1073500 USD |
Profile of Aytu BioPharma
| Country | United States |
| State | CO |
| City | Denver |
| Address | Denver Corporate Center III |
| ZIP | 80237 |
| Phone | 720 437 6580 |
| Website | https://aytubio.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 82 |
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
Q&A For Aytu BioPharma Stock
What is a current AYTU stock price?
Aytu BioPharma AYTU stock price today per share is 2.25 USD.
How to purchase Aytu BioPharma stock?
You can buy AYTU shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aytu BioPharma?
The stock symbol or ticker of Aytu BioPharma is AYTU.
Which industry does the Aytu BioPharma company belong to?
The Aytu BioPharma industry is Drug Manufacturers - Specialty & Generic.
How many shares does Aytu BioPharma have in circulation?
The max supply of Aytu BioPharma shares is 10.73M.
What is Aytu BioPharma Price to Earnings Ratio (PE Ratio)?
Aytu BioPharma PE Ratio is now.
What was Aytu BioPharma earnings per share over the trailing 12 months (TTM)?
Aytu BioPharma EPS is -4.61 USD over the trailing 12 months.
Which sector does the Aytu BioPharma company belong to?
The Aytu BioPharma sector is Healthcare.
Aytu BioPharma AYTU included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Capital Market Composite
RCMP
US
|
146.53 USD — |
-0.75
|
— — | 144.14 USD — | 148.72 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
- {{ link.label }} {{link}}